Department of Biological Sciences, National Sun Yat-sen University, Kaohsiung 80424, Taiwan, ROC; Department of Pathology, Kaohsiung Armed Forces General Hospital, Kaohsiung 80284, Taiwan, ROC.
Department of Biological Sciences, National Sun Yat-sen University, Kaohsiung 80424, Taiwan, ROC.
Biomed Pharmacother. 2021 Feb;134:111046. doi: 10.1016/j.biopha.2020.111046. Epub 2020 Dec 16.
Transforming growth factor-β (TGF-β) is a multifunctional cytokine that is involved in proliferation, metastasis, and many other important processes in malignancy. Inhibitors targeting TGF-β have been considered by pharmaceutical companies for cancer therapy, and some of them are in clinical trial now. Unfortunately, several of these programs have recently been relinquished, and most companies that remain in the contest are progressing slowly and cautiously. This review summarizes the TGF-β signal transduction pathway, its roles in oncogenesis and fibrotic diseases, and advancements in antibodies and small-molecule inhibitors of TGF-β.
转化生长因子-β（TGF-β）是一种多功能细胞因子，参与恶性肿瘤的增殖、转移和许多其他重要过程。靶向 TGF-β 的抑制剂已被制药公司考虑用于癌症治疗，其中一些目前正在临床试验中。不幸的是，这些项目中的几个最近已经被放弃，而剩下的大多数公司进展缓慢且谨慎。本综述总结了 TGF-β 信号转导通路及其在肿瘤发生和纤维化疾病中的作用，以及 TGF-β 抗体和小分子抑制剂的进展。
